Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5456693 | 0.99 | CYP1A2 (0.42) | CYP1A2CYP2D6CYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL5456536 | 0.93 | ADRB2 (0.45) | ALDH1A1SMN1; SMN2HRH1KDM4EADRB2 | |
| Hydrochloric Acid SCHEMBL5450232 | 0.92 | ADRB2 (0.44) | ALDH1A1SMN1; SMN2HRH1KDM4EADRB2 | |
| SCHEMBL5454243 | 0.89 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2KDM4EPOLBMAPT | |
| SCHEMBL11684336 | 0.86 | GAA (0.46) | CYP1A2CYP2C19ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL17242146 | 0.84 | CYP1A2 (0.44) | CYP1A2CYP2D6CYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL5443168 | 0.83 | HPGD (0.37) | ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL5446680 | 0.82 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL5444761 | 0.82 | ERN1 (0.40) | ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL5452274 | 0.82 | EGFR (0.41) | ALDH1A1SMN1; SMN2KDM4EPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007506661-A | — | — | 2007-03-22 | — | — | JP | claimed |
| US-20070037846-A1 | Pyrazolidinedione derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-15 | — | — | US | claimed |
| EP-1638540-A2 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2006-03-29 | — | — | EP | claimed |
| WO-2005000281-A2 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-01-06 | — | — | WO | claimed |
| US-20070037846-A1 | Pyrazolidinedione derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-15 | — | — | US | disclosed |
| EP-1638540-A2 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000281-A2 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037846-A1 | Pyrazolidinedione derivatives | P2RY1, P2RY4, P2RY2 | CYP1A2 456/4885CYP2D6 1005/4885CYP2C19 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.